Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Artidis, a Switzerland-based cancer diagnostics spinout of the Biozentrum at University of Basel, obtained CHF8.8m ($8.9m) in seed funding yesterday from medical instrument supplier SMD MedicalTrade, investment firm Bernina Bioinvest and unspecified family offices and individuals. The money will prepare Artidis’s nanomechanics-powered diagnostics for lung and breast cancer ahead of a multi-centre clinical study, with the aim of launching to market in 2021. Artidis was formed in 2017 by its chief medical officer Marko Loparic – a product lead at…